ELDN Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
22.9M
+8.0%
21.2M
-1.4%
21.5M
+12.7%
19.1M
-22.9%
24.7M
R&D
18.2M
+6.0%
17.2M
-1.7%
17.5M
+16.8%
15.0M
-26.2%
20.3M
SG&A
4.6M
+16.4%
4.0M
-0.2%
4.0M
-2.6%
4.1M
-8.0%
4.5M
Operating Income
-22869000
-8.0%
-21181000
+1.4%
-21484000
-12.7%
-19070000
+22.9%
-24733000
EBITDA
-22869000
-8.0%
-21181000
+1.4%
-21484000
-12.7%
-19070000
+22.9%
-24733000
Net Income
-31630000
+18.9%
-39025000
-273.6%
-10447000
+40.2%
-17459000
-55.7%
-11216000
EPS (Basic)
$-0.27
+18.2%
$-0.33
-135.7%
$-0.14
+33.3%
$-0.21
-61.5%
$-0.13
EPS (Diluted)
$-0.27
+18.2%
$-0.33
-135.7%
$-0.14
+33.3%
$-0.21
-61.5%
$-0.13
Shares (Diluted)
113.6M
+1.1%
112.4M
+17.2%
95.9M
+24.3%
77.2M
+0.0%
77.2M
Eledon Pharmaceuticals (ELDN) โ€” Financials